HR Execs on the Move

Syneos Health

www.syneoshealth.com

 
"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Chris Hodes
Regional Sales Director Profile
Steve O'Brien
SVP, Talent Acquisition Profile
Hillary Bochniak
Chief Human Resources Officer Profile
Robyn Aycock
Regional Sales Director-Southeast Profile
Stanford Rudnick
Interim Chief Financial Officer and Chief Strategy Officer Profile

Similar Companies

Refresh Mental Health

Refresh Mental Health is the parent company of premiere outpatient mental health, substance abuse & eating disorder practices across the United States.

Recursion Pharmaceuticals

Recursion Pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics.

Advanced Recovery Systems

Find a rehab center to treat your drug or alcohol addiction, eating disorder, or mental illness. Connect with us and get help for your addiction.

natures sunshine products

natures sunshine products is a Provo, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.